|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TUBA3D |
Gene summary for TUBA3D |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TUBA3D | Gene ID | 113457 |
| Gene name | tubulin alpha 3d | |
| Gene Alias | H2-ALPHA | |
| Cytomap | 2q21.1 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q13748 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 113457 | TUBA3D | GSM4909302 | Human | Breast | IDC | 8.86e-14 | 3.56e-01 | 0.1545 |
| 113457 | TUBA3D | GSM4909304 | Human | Breast | IDC | 1.27e-97 | 1.38e+00 | 0.1636 |
| 113457 | TUBA3D | GSM4909308 | Human | Breast | IDC | 1.64e-21 | 5.06e-01 | 0.158 |
| 113457 | TUBA3D | NCCBC11 | Human | Breast | DCIS | 7.89e-13 | 7.25e-01 | 0.1232 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0502023 | Breast | IDC | Prion disease | 102/867 | 273/8465 | 3.70e-34 | 4.01e-32 | 3.00e-32 | 102 |
| hsa0513224 | Breast | IDC | Salmonella infection | 55/867 | 249/8465 | 2.07e-08 | 4.49e-07 | 3.36e-07 | 55 |
| hsa0502033 | Breast | IDC | Prion disease | 102/867 | 273/8465 | 3.70e-34 | 4.01e-32 | 3.00e-32 | 102 |
| hsa0513234 | Breast | IDC | Salmonella infection | 55/867 | 249/8465 | 2.07e-08 | 4.49e-07 | 3.36e-07 | 55 |
| hsa0501243 | Breast | DCIS | Parkinson disease | 106/846 | 266/8465 | 1.64e-39 | 5.29e-37 | 3.90e-37 | 106 |
| hsa0502043 | Breast | DCIS | Prion disease | 100/846 | 273/8465 | 1.44e-33 | 1.55e-31 | 1.14e-31 | 100 |
| hsa0501643 | Breast | DCIS | Huntington disease | 101/846 | 306/8465 | 1.54e-29 | 1.24e-27 | 9.13e-28 | 101 |
| hsa0501043 | Breast | DCIS | Alzheimer disease | 105/846 | 384/8465 | 3.23e-23 | 1.49e-21 | 1.10e-21 | 105 |
| hsa0501443 | Breast | DCIS | Amyotrophic lateral sclerosis | 101/846 | 364/8465 | 7.14e-23 | 2.88e-21 | 2.12e-21 | 101 |
| hsa0502243 | Breast | DCIS | Pathways of neurodegeneration - multiple diseases | 114/846 | 476/8465 | 4.74e-20 | 1.53e-18 | 1.13e-18 | 114 |
| hsa0513243 | Breast | DCIS | Salmonella infection | 55/846 | 249/8465 | 8.71e-09 | 1.87e-07 | 1.38e-07 | 55 |
| hsa0513043 | Breast | DCIS | Pathogenic Escherichia coli infection | 42/846 | 197/8465 | 1.40e-06 | 2.15e-05 | 1.59e-05 | 42 |
| hsa0414541 | Breast | DCIS | Phagosome | 35/846 | 152/8465 | 1.67e-06 | 2.45e-05 | 1.81e-05 | 35 |
| hsa0453044 | Breast | DCIS | Tight junction | 37/846 | 169/8465 | 3.07e-06 | 4.20e-05 | 3.09e-05 | 37 |
| hsa0421041 | Breast | DCIS | Apoptosis | 29/846 | 136/8465 | 5.92e-05 | 5.97e-04 | 4.40e-04 | 29 |
| hsa0501253 | Breast | DCIS | Parkinson disease | 106/846 | 266/8465 | 1.64e-39 | 5.29e-37 | 3.90e-37 | 106 |
| hsa0502053 | Breast | DCIS | Prion disease | 100/846 | 273/8465 | 1.44e-33 | 1.55e-31 | 1.14e-31 | 100 |
| hsa0501653 | Breast | DCIS | Huntington disease | 101/846 | 306/8465 | 1.54e-29 | 1.24e-27 | 9.13e-28 | 101 |
| hsa0501053 | Breast | DCIS | Alzheimer disease | 105/846 | 384/8465 | 3.23e-23 | 1.49e-21 | 1.10e-21 | 105 |
| hsa0501453 | Breast | DCIS | Amyotrophic lateral sclerosis | 101/846 | 364/8465 | 7.14e-23 | 2.88e-21 | 2.12e-21 | 101 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TUBA3D | SNV | Missense_Mutation | rs771034023 | c.613G>A | p.Asp205Asn | p.D205N | Q13748 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.964) | TCGA-A2-A0YM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TUBA3D | SNV | Missense_Mutation | rs530707778 | c.49N>A | p.Gly17Ser | p.G17S | Q13748 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.994) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TUBA3D | SNV | Missense_Mutation | novel | c.381T>A | p.Asp127Glu | p.D127E | Q13748 | protein_coding | tolerated_low_confidence(0.24) | benign(0.006) | TCGA-LL-A6FP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| TUBA3D | SNV | Missense_Mutation | c.143C>G | p.Ser48Cys | p.S48C | Q13748 | protein_coding | deleterious_low_confidence(0.04) | benign(0.042) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| TUBA3D | SNV | Missense_Mutation | novel | c.52N>C | p.Asn18His | p.N18H | Q13748 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.991) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| TUBA3D | SNV | Missense_Mutation | rs752428849 | c.728G>A | p.Arg243Gln | p.R243Q | Q13748 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.958) | TCGA-AA-3875-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TUBA3D | SNV | Missense_Mutation | rs756867847 | c.1186N>A | p.Asp396Asn | p.D396N | Q13748 | protein_coding | deleterious_low_confidence(0.01) | benign(0.077) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
| TUBA3D | SNV | Missense_Mutation | c.1118N>A | p.Arg373Gln | p.R373Q | Q13748 | protein_coding | deleterious_low_confidence(0.02) | benign(0.364) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TUBA3D | SNV | Missense_Mutation | novel | c.476N>C | p.Val159Ala | p.V159A | Q13748 | protein_coding | tolerated_low_confidence(0.06) | benign(0.028) | TCGA-AG-3726-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TUBA3D | SNV | Missense_Mutation | rs752428849 | c.728N>A | p.Arg243Gln | p.R243Q | Q13748 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.958) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 113457 | TUBA3D | DRUGGABLE GENOME | ZAMPANOLIDE | ZAMPANOLIDE | 19877653 | |
| 113457 | TUBA3D | DRUGGABLE GENOME | VORINOSTAT | VORINOSTAT | 20491440 | |
| 113457 | TUBA3D | DRUGGABLE GENOME | inhibitor | CHEMBL538943 | VINORELBINE TARTRATE | |
| 113457 | TUBA3D | DRUGGABLE GENOME | inhibitor | CHEMBL1201748 | CABAZITAXEL | |
| 113457 | TUBA3D | DRUGGABLE GENOME | NSC-751382 | CHEMBL1935538 | 22435708 | |
| 113457 | TUBA3D | DRUGGABLE GENOME | inhibitor | CHEMBL3545252 | DOCETAXEL | |
| 113457 | TUBA3D | DRUGGABLE GENOME | inhibitor | CHEMBL49642 | INDIBULIN | |
| 113457 | TUBA3D | DRUGGABLE GENOME | inhibitor | CHEMBL1683544 | ERIBULIN MESYLATE | |
| 113457 | TUBA3D | DRUGGABLE GENOME | CHEMBL2105643 | FOSBRETABULIN TROMETHAMINE | ||
| 113457 | TUBA3D | DRUGGABLE GENOME | CHEMBL2304041 | SAGOPILONE |
| Page: 1 2 3 4 5 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |